Literature DB >> 16061559

Spectrum of splicing errors caused by CHRNE mutations affecting introns and intron/exon boundaries.

K Ohno1, A Tsujino, X-M Shen, M Milone, A G Engel.   

Abstract

BACKGROUND: Mutations in CHRNE, the gene encoding the muscle nicotinic acetylcholine receptor epsilon subunit, cause congenital myasthenic syndromes. Only three of the eight intronic splice site mutations of CHRNE reported to date have had their splicing consequences characterised.
METHODS: We analysed four previously reported and five novel splicing mutations in CHRNE by introducing the entire normal and mutant genomic CHRNEs into COS cells. RESULTS AND
CONCLUSIONS: We found that short introns (82-109 nucleotides) favour intron retention, whereas medium to long introns (306-1210 nucleotides) flanking either or both sides of an exon favour exon skipping. Two mutations are of particular interest. Firstly, a G-->T substitution at the 3' end of exon 8 predicts an R286M missense mutation, but instead results in skipping of exon 8. In human genes, a mismatch of the last exonic nucleotide to U1 snRNP is frequently compensated by a matching nucleotide at intron position +6. CHRNE intron 8 has a mismatch at position +6, and accordingly fails to compensate for the exonic mutation at position -1. Secondly, a 16 bp duplication, giving rise to two 3' splice sites (g.IVS10-9_c.1167dup16), results in silencing of the downstream 3' splice site. This conforms to the scanning model of recognition of the 3' splice site, which predicts that the first "ag" occurring after the branch point is selected for splicing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061559      PMCID: PMC1736110          DOI: 10.1136/jmg.2004.026682

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  7 in total

1.  Identification of previously unreported mutations in CHRNA1, CHRNE and RAPSN genes in three unrelated Italian patients with congenital myasthenic syndromes.

Authors:  Raffaella Brugnoni; Lorenzo Maggi; Eleonora Canioni; Isabella Moroni; Chiara Pantaleoni; Stefano D'Arrigo; Daria Riva; Ferdinando Cornelio; Pia Bernasconi; Renato Mantegazza
Journal:  J Neurol       Date:  2010-02-16       Impact factor: 4.849

2.  Natural variation in the splice site strength of a clock gene and species-specific thermal adaptation.

Authors:  Kwang Huei Low; Cecilia Lim; Hyuk Wan Ko; Isaac Edery
Journal:  Neuron       Date:  2008-12-26       Impact factor: 17.173

3.  Interpretable prioritization of splice variants in diagnostic next-generation sequencing.

Authors:  Daniel Danis; Julius O B Jacobsen; Leigh C Carmody; Michael A Gargano; Julie A McMurry; Ayushi Hegde; Melissa A Haendel; Giorgio Valentini; Damian Smedley; Peter N Robinson
Journal:  Am J Hum Genet       Date:  2021-07-21       Impact factor: 11.025

4.  Aberrant 3' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Authors:  Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2006-09-08       Impact factor: 16.971

5.  Competitive regulation of alternative splicing and alternative polyadenylation by hnRNP H and CstF64 determines acetylcholinesterase isoforms.

Authors:  Mohammad Nazim; Akio Masuda; Mohammad Alinoor Rahman; Farhana Nasrin; Jun-Ichi Takeda; Kenji Ohe; Bisei Ohkawara; Mikako Ito; Kinji Ohno
Journal:  Nucleic Acids Res       Date:  2017-02-17       Impact factor: 16.971

6.  Splicing Factor SRSF1 Is Essential for Satellite Cell Proliferation and Postnatal Maturation of Neuromuscular Junctions in Mice.

Authors:  Yuguo Liu; Yangjun Luo; Lei Shen; Ruochen Guo; Zheng Zhan; Ningyang Yuan; Rula Sha; Wenju Qian; Zhenzhen Wang; Zhiqin Xie; Wenwu Wu; Ying Feng
Journal:  Stem Cell Reports       Date:  2020-09-03       Impact factor: 7.765

7.  Acetylcholine receptor subunit expression in Huntington's disease mouse muscle.

Authors:  Briana Simpson; Mark M Rich; Andrew A Voss; Robert J Talmadge
Journal:  Biochem Biophys Rep       Date:  2021-12-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.